Literature DB >> 22217610

Cerebrovascular complications of neurocysticercosis.

Juan Manuel Marquez1, Antonio Arauz.   

Abstract

BACKGROUND: It is well established that several infectious diseases can directly lead to ischemic or hemorrhagic stroke. Neurocysticercosis (NCC), caused by infection of the human central nervous system with the parasite Taenia solium, is recognized as an important public health problem in developing countries. The clinical manifestations of NCC are nonspecific and varied depending on the number and topography of lesions. Cerebrovascular disease is a relatively common but underrecognized complication of NCC; published data indicate that the incidence of stroke is between 4% and 12% in patients with NCC, depicting a clear relationship among these 2 pathologies. REVIEW
SUMMARY: We review the cerebrovascular complications of NCC including the possible role of NCC as a cerebrovascular risk factor, including epidemiology, pathogenesis, diagnosis, and management of the cerebrovascular complications derived from cysticercal infarction and those associated with the use of anticysticercal drugs. Common and uncommon clinical manifestations, localization of stroke, and associated syndromes are discussed along with their prognostic significance.
CONCLUSIONS: Although an underrecognized cause of stroke, present preponderantly in undeveloped countries, NCC still causes significant incapacity and even death in young patients suffering from stroke in the absence of cerebrovascular risk factors; hence, neurologists should become familiar with this potential complication.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22217610     DOI: 10.1097/NRL.0b013e31823d7a80

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  9 in total

1.  Neurocysticercosis.

Authors:  Oscar H Del Brutto
Journal:  Neurohospitalist       Date:  2014-10

Review 2.  Under seize: neurocysticercosis in an immigrant woman and review of a growing neglected disease.

Authors:  Meredith Bock; Hector H Garcia; Peter Chin-Hong; Sanjiv M Baxi
Journal:  BMJ Case Rep       Date:  2015-12-18

Review 3.  Neuroimaging in Central Nervous System Infections.

Authors:  Nathaniel C Swinburne; Anmol G Bansal; Amit Aggarwal; Amish H Doshi
Journal:  Curr Neurol Neurosci Rep       Date:  2017-06       Impact factor: 5.081

Review 4.  Conservative management of neurocysticercosis in a patient with hematopoietic stem cell transplantation: a case report and review.

Authors:  S Purvey; K Lu; S K Mukkamalla; P Anandi; B Dumitriu; S Kranick; D A Hammoud; E O'Connell; A L Oh; J Barrett; S Mahanty; M Battiwalla
Journal:  Transpl Infect Dis       Date:  2015-06-01       Impact factor: 2.228

5.  The importance of neurocysticercosis in stroke in rural areas of a developing Latin American country.

Authors:  Oscar H Del Brutto; Julio Lama
Journal:  Am J Trop Med Hyg       Date:  2013-07-08       Impact factor: 2.345

6.  Next generation sequencing based pathogen analysis in a patient with neurocysticercosis: a case report.

Authors:  Ping Liu; Xing Weng; Jiajia Zhou; Xiaolin Xu; Fangping He; Yue Du; Honglong Wu; Yanping Gong; Guoping Peng
Journal:  BMC Infect Dis       Date:  2018-03-06       Impact factor: 3.090

7.  Report of three imported cases of neurocysticercosis in Guadeloupe.

Authors:  R Blaizot; B Melot; K Schepers; M Nicolas; S Gaumond; P Poullain; L Belaye; A Lannuzel; B Hoen
Journal:  BMC Infect Dis       Date:  2017-01-31       Impact factor: 3.090

8.  Natural History of Treated Subarachnoid Neurocysticercosis.

Authors:  Theodore E Nash; Elise M O'Connell; Dima A Hammoud; Lauren Wetzler; JeanAnne M Ware; Siddhartha Mahanty
Journal:  Am J Trop Med Hyg       Date:  2020-01       Impact factor: 2.345

Review 9.  Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases.

Authors:  Fabian Lötscher; Roxana Pop; Pascal Seitz; Mike Recher; Luca Seitz
Journal:  Curr Rheumatol Rep       Date:  2022-08-03       Impact factor: 4.686

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.